Back to Search Start Over

Four disruptive strategies for removing drug discovery bottlenecks

Authors :
Ekins, Sean
Waller, Chris L.
Bradley, Mary P.
Clark, Alex M.
Williams, Antony J.
Source :
Drug Discovery Today. Mar2013, Vol. 18 Issue 5/6, p265-271. 7p.
Publication Year :
2013

Abstract

Drug discovery is shifting focus from industry to outside partners and, in the process, creating new bottlenecks. Technologies like high throughput screening (HTS) have moved to a larger number of academic and institutional laboratories in the USA, with little coordination or consideration of the outputs and creating a translational gap. Although there have been collaborative public–private partnerships in Europe to share pharmaceutical data, the USA has seemingly lagged behind and this may hold it back. Sharing precompetitive data and models may accelerate discovery across the board, while finding the best collaborators, mining social media and mobile approaches to open drug discovery should be evaluated in our efforts to remove drug discovery bottlenecks. We describe four strategies to rectify the current unsustainable situation. [Copyright &y& Elsevier]

Details

Language :
English
ISSN :
13596446
Volume :
18
Issue :
5/6
Database :
Academic Search Index
Journal :
Drug Discovery Today
Publication Type :
Academic Journal
Accession number :
85876746
Full Text :
https://doi.org/10.1016/j.drudis.2012.10.007